These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 3536423)

  • 21. Panic disorder in a patient taking oxaprozin.
    Hough DW; Sellers R; Cantilena LR
    Am J Psychiatry; 1995 Jan; 152(1):149. PubMed ID: 7802107
    [No Abstract]   [Full Text] [Related]  

  • 22. Toxic epidermal necrolysis following treatment with oxaprozin.
    Carucci JA; Cohen DE
    Int J Dermatol; 1999 Mar; 38(3):233-4. PubMed ID: 10208628
    [No Abstract]   [Full Text] [Related]  

  • 23. Double-blind study on the interaction of oxaprozin with metoprolol in hypertensives.
    Halabi A; Linde M; Zeidler H; König J; Kirch W
    Cardiovasc Drugs Ther; 1989 Jun; 3(3):441-3. PubMed ID: 2487540
    [No Abstract]   [Full Text] [Related]  

  • 24. Health-related quality-of-life effects of oxaprozin and nabumetone in patients with osteoarthritis of the knee.
    Zhao SZ; Dedhiya SD; Bocanegra TS; Fort JG; Kuss ME; Rush SM
    Clin Ther; 1999 Jan; 21(1):205-17. PubMed ID: 10090436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics of oxaprozin.
    Davies NM
    Clin Pharmacokinet; 1998 Dec; 35(6):425-36. PubMed ID: 9884815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suprofen. A review of its pharmacodynamic and pharmacokinetic properties, and analgesic efficacy.
    Todd PA; Heel RC
    Drugs; 1985 Dec; 30(6):514-38. PubMed ID: 3908075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulindac: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases.
    Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1978 Aug; 16(2):97-114. PubMed ID: 352667
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of co-administered drugs on oxaprozin binding to human serum albumin.
    Aubry AF; Markoglou N; Adams MH; Longstreth J; Wainer IW
    J Pharm Pharmacol; 1995 Nov; 47(11):937-44. PubMed ID: 8708989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tiaprofenic acid. A reappraisal of its pharmacological properties and use in the management of rheumatic diseases.
    Plosker GL; Wagstaff AJ
    Drugs; 1995 Dec; 50(6):1050-75. PubMed ID: 8612471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological profile of oxaprozin eye drops.
    Bucolo C; Maltese A
    J Ocul Pharmacol Ther; 2002 Feb; 18(1):75-81. PubMed ID: 11858617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics.
    Karim A; Noveck R; McMahon FG; Smith M; Crosby S; Adams M; Wilton J
    J Clin Pharmacol; 1997 Apr; 37(4):267-78. PubMed ID: 9115051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug.
    Zhou XP; Zhang MX; Sun W; Yang XH; Wang GS; Sui DY; Yu XF; Qu SC
    Biol Pharm Bull; 2009 Dec; 32(12):1986-90. PubMed ID: 19952416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxaprozin-induced symptomatic hepatotoxicity.
    Kethu SR; Rukkannagari S; Lansford CL
    Ann Pharmacother; 1999 Sep; 33(9):942-4. PubMed ID: 10492496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre double-blind comparison of oxaprozin aspirin therapy on rheumatoid arthritis.
    Hubsher JA; Ballard IM; Walker BR; Gold JA
    J Int Med Res; 1979; 7(1):69-76. PubMed ID: 369925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.
    Friedel HA; Langtry HD; Buckley MM
    Drugs; 1993 Jan; 45(1):131-56. PubMed ID: 7680981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, parallel trial of oxaprozin versus naproxen in the treatment of osteoarthritis.
    Ginsberg F; Famaey JP
    Curr Med Res Opin; 1984; 8(10):689-95. PubMed ID: 6373152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.
    Scavone JM; Greenblatt DJ; Matlis R; Harmatz JS
    Eur J Clin Pharmacol; 1986; 31(3):371-4. PubMed ID: 3792438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxic eruption in a woman with chronic arthritis.
    Abate KL; Malkinson FD
    Arch Dermatol; 1999 Jan; 135(1):81-6. PubMed ID: 9935389
    [No Abstract]   [Full Text] [Related]  

  • 39. Gastrointestinal blood loss of oxaprozin and aspirin with placebo control.
    Lussier A; LeBel E; Tétreault L
    J Clin Pharmacol; 1982 Apr; 22(4):173-8. PubMed ID: 6980231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxaprozin prodrug as safer nonsteroidal anti-inflammatory drug: Synthesis and pharmacological evaluation.
    Peesa JP; Atmakuri LR; Yalavarthi PR; Mandava Venkata BR; Rasheed A; Pachava V
    Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29283449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.